DUBLIN--(BUSINESS WIRE)-- <\/p>\n
Research and Markets (http:\/\/www.researchandmarkets.com\/research\/g525xq\/multiple<\/a>) has announced the addition of Decision Resources, Inc's new report \"Multiple Sclerosis (Event Driven)\" to their offering. <\/p>\n The market for disease-modifying multiple sclerosis (MS) therapies is poised to undergo a dramatic transformation as a suite of new and promising emerging therapies enter the market over the next five years, including the first, and much-anticipated, orally delivered products. Novel therapies will drive growth of the MS market through 2015, but the gains will be constrained by a conservative prescriber base and lingering favoritism for time-tested current agents, at least over the near term, coupled with forecasted generics competition. All new agents are expected to be approved to treat relapsing forms of MS; ample opportunity will remain for therapies to treat the underserved population of patients who suffer progressive forms of the disease. <\/p>\n Key Topics Covered: <\/p>\n Executive Summary <\/p>\n What are the key parameters of the multiple sclerosis market? <\/p>\n What factors are driving the market for multiple sclerosis therapies? <\/p>\n What factors are constraining the market for multiple sclerosis therapies? <\/p>\n What are the drug development activities of note in multiple sclerosis? <\/p>\n What do the experts say? <\/p>\n<\/p>\n Read more: DUBLIN--(BUSINESS WIRE)-- Research and Markets (http:\/\/www.researchandmarkets.com\/research\/g525xq\/multiple<\/a>) has announced the addition of Decision Resources, Inc's new report \"Multiple Sclerosis (Event Driven)\" to their offering. The market for disease-modifying multiple sclerosis (MS) therapies is poised to undergo a dramatic transformation as a suite of new and promising emerging therapies enter the market over the next five years, including the first, and much-anticipated, orally delivered products. Novel therapies will drive growth of the MS market through 2015, but the gains will be constrained by a conservative prescriber base and lingering favoritism for time-tested current agents, at least over the near term, coupled with forecasted generics competition Continue reading
\nResearch and Markets: Multiple Sclerosis (Event Driven)<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"